Pharmaceutical firm National Institute for Health and Care Excellence has agreed to buy Kite Pharma , a company that has developed a gene therapy for treating cancers. Through the deal, Gilead Sciences will obtain rights to Kite Pharma 's CAR-T therapy, a treatment for blood cancers such as lymphoma. The therapy reprogrammes the DNA within individuals' immune cells to attack the disease. Although no official pricing for such therapies has been published, the UK 's National Institute for Health and Care Excellence has said that $ $11.9 billion for a 50 -off treatment for a young patient with leukaemia is justifiable.
Pharmaceutical firm Gilead Sciences has agreed to buy Kite Pharma, a company that has developed a gene therapy for treating cancers. Through the deal, Gilead will obtain rights to Kite's CAR-T therapy, a treatment for blood cancers such as lymphoma. The therapy reprogrammes the DNA within individuals' immune cells to attack the disease. Although no official pricing for such therapies has been published, the UK's National Institute for Health and Care Excellence has said that $649,000 for a one-off treatment for a young patient with leukaemia is justifiable.